Just weeks after Novo Nordisk introduced that its weight problems drug Wegovy minimize the danger of coronary heart problems in a significant trial, the corporate now has outcomes from a special examine displaying the remedy also can profit individuals with a standard sort of coronary heart failure.
The outcomes, revealed Friday within the New England Journal of Medication, discovered that amongst individuals with weight problems and coronary heart failure with preserved ejection fraction, or HFpEF, these taking Wegovy skilled higher enhancements in signs and bodily perform in contrast with these on placebo. The enhancements have been higher than what’s been seen in trials of another HFpEF therapies.
Novo beforehand shared topline ends in investor calls, however the brand new examine comprises the complete findings, that are additionally being introduced on the European Society of Cardiology convention this week.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED
